Hummingbird BioscienceInvestment company Frazier Life Sciences has launched the virtual ADC company Callio Therapeutics Inc by licencing Hummingbird Bioscience’s TopDDRive dual payload ADC technology and co-leading a US$187m financing round with French Jeito Capital and other investors.
ADVERTISEMENT